Results 91 to 100 of about 71,118 (301)

Benign Migratory Glossitis in a Patient With Cholangiocarcinoma due to Targeted Drug Therapy. [PDF]

Clin Case Rep
Oral Manifestation of Targeted Therapy: Benign Migratory Glossitis. ABSTRACT During the course of targeted drug therapy, a cancer patient may manifest a myriad of systemic and oral toxicities. This has a direct impact on the patient's QOL. This clinical image highlights a rarely‐encountered oral mucosal alteration called benign migratory glossitis in a
Gurav S, Singh GP, Jain R.
europepmc   +2 more sources

Diagnosis of cholangiocarcinoma [PDF]

HPB, 2008
Cholangiocarcinoma is suspected based on signs of biliary obstruction, abnormal liver function tests, elevated tumor markers (carbohydrate antigen 19-9 and carcinoembryonic antigen), and ultrasonography showing a bile stricture or a mass, especially in intrahepatic cholangiocarcinoma.
openaire   +2 more sources

Cholangiocarcinoma. Epidemiology, classification, diagnosis, treatment methods (literature review)

Cholangiocarcinoma ranks second in the prevalence among primary malignant neoplasms of the liver. The paper discusses epidemiology, classification, risk factors of the disease, as well as the treatment approaches used all over the world, including ...
Artem A. Vovchenko, Leonid O. Petrov, Valery V. Kucherov, Alexandra G. Zamotina, Artur P. Petrosyan, Natalia A. Falaleeva   +5 more
core   +1 more source

Molecular Tumor Boards in Malignant Melanoma: Uncovering Challenges and Opportunities in a Bicenter Retrospective Analysis in Germany

International Journal of Cancer, EarlyView.
Molecular tumor boards (MTB), interdisciplinary teams that use tumor genomic data to guide personalized treatment decisions, have emerged as a promising strategy in melanoma care, although their real‐world clinical impact remains uncertain. This retrospective study evaluated advanced melanoma patients to assess molecularly guided treatment ...
Glenn Geidel, Theresa Lowinus, Patrick Metzger, Rebecca Czurda, Vincent Schipperges, Ulrike Paul, Alessandra Rünger, Julian Kött, Isabel Heidrich, Saskia Lehr, Julia Kühn, Heiko Becker, Cornelius Miething, Martin Werner, Silke Laßmann, Justus Duyster, Tilman Brummer, Ronald Simon, Winfried Alsdorf, Maximilian Christopeit, Carsten Bokemeyer, Kilian Eyerich, Stefan W. Schneider, David Rafei, Melanie Börries, Frank Meiss, Christoffer Gebhardt   +26 more
wiley   +1 more source

Discovery of novel serum peptide biomarkers for cholangiocarcinoma recurrence through MALDI-TOF MS and LC–MS/MS peptidome analysis

Scientific Reports
Cholangiocarcinoma (CCA) is an aggressive cancer originating from bile duct epithelial cells, with a high rate of recurrence following surgical resection. Recurrence is categorized as early linked to aggressive tumor biology than late recurrence.
Vasin Thanasukarn, Piya Prajumwongs, Nattha Muangritdech, Watcharin Loilome, Nisana Namwat, Poramate Klanrit, Arporn Wangwiwatsin, Sawanya Charoenlappanit, Janthima Jaresitthikunchai, Sittiruk Roytrakul, Attapol Titapun   +10 more
doaj   +1 more source

Inhibition of -type amino acid transporter 1 activity as a new therapeutic target for cholangiocarcinoma treatment

Tumor Biology, 2017
Unlike normal cells, cancer cells undergo unlimited growth and multiplication, causing them to require massive amounts of amino acid to support their continuous metabolism. Among the amino acid transporters expressed on the plasma membrane, l- type amino
Supak Yothaisong, Hasaya Dokduang, Naohiko Anzai, Keitaro Hayashi, Nisana Namwat, Puangrat Yongvanit, Sakkarn Sangkhamanon, Promsuk Jutabha, Hitoshi Endou, Watcharin Loilome   +9 more
doaj   +1 more source

Overexpression of a panel of cancer stem cell markers enhances the predictive capability of the progression and recurrence in the early stage cholangiocarcinoma

Journal of Translational Medicine, 2020
Background Cancer recurrence is the important problem of cholangiocarcinoma (CCA) patients, lead to a very high mortality rate. Therefore, the identification of candidate markers to predict CCA recurrence is needed in order to effectively manage the ...
Sureerat Padthaisong, Malinee Thanee, Nisana Namwat, Jutarop Phetcharaburanin, Poramate Klanrit, Narong Khuntikeo, Attapol Titapun, Sakkarn Sungkhamanon, Hideyuki Saya, Watcharin Loilome   +9 more
doaj   +1 more source

The Endothelial CXCR Family in Vascular Health and Disease

iNew Medicine, EarlyView.
ABSTRACT Endothelial cells (ECs) form the dynamic interface between blood and tissue, serving as key regulators of vascular homeostasis, inflammation, and repair. Among the molecular systems governing endothelial behavior, the C‐X‐C motif chemokine receptor (CXCR) family—originally characterized in immunology for its roles in leukocyte trafficking and ...
Zhiming Wu, Yandi Wu, Suowen Xu, Yu Huang, Li Wang   +4 more
wiley   +1 more source

c‐Met‐Targeted Imaging Agents: Progress and Challenges

iRADIOLOGY, EarlyView.
This review summarizes recent advances in c‐Met‐targeted imaging probes, including hepatocyte growth factor (HGF) ligands, antibodies, peptides, and small molecules across magnetic resonance imaging (MRI), positron emission tomography (PET), single‐photon emission computed tomography (SPECT), and optical imaging modalities.
Yonghao Li, Aiyan Ji, Qihang Ding, Hongyue Lou, Zhen Cheng   +4 more
wiley   +1 more source

Serum Midkine as a Biomarker for Hepatocellular Carcinoma Treatment Response and Prognostication

Journal of Clinical Laboratory Analysis, EarlyView.
Up‐to‐date, tumor markers are considered more helpful in the evaluation of treatment response and prognostication rather than diagnosis. Identifying a valid biomarker to help clinical management of hepatocellular carcinoma (HCC) is still a challenge, especially the alpha‐fetoprotein (AFP) negative HCC. This study evaluated the efficacy of serum Midkine
Yanfang Luo, Qiuwei Lu, Jing Huang, Liejun Jiang   +3 more
wiley   +1 more source